EBS
Emergent Biosolutions Inc
NYSE · Biotechnology
$10.92
+0.38 (+3.61%)
Open$10.65
Previous Close$10.54
Day High$10.96
Day Low$10.40
52W High$14.06
52W Low$4.02
Volume—
Avg Volume633.5K
Market Cap573.52M
P/E Ratio7.56
EPS$1.29
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+148.0% upside
Current
$10.92
$10.92
Target
$27.08
$27.08
$18.81
$27.08 avg
$37.55
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 1.03B | 1.24B | 343.48M |
| Net Income | -188,872,292 | -203,574,925 | -73,282,630 |
| Profit Margin | -18.3% | -17.4% | -21.3% |
| EBITDA | -6,738,311 | -7,666,341 | -100,144,769 |
| Free Cash Flow | — | — | -51,592,821 |
| Rev Growth | -16.5% | -16.5% | +21.6% |
| Debt/Equity | 1.37 | 1.37 | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |